A large observational study has investigated the cardiovascular effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors in new users compared with new users of other glucose-lowering drugs.¹ Previously published studies in patients with type 2 diabetes and a high cardiovascular risk profile have reported reductions in cardiovascular outcomes with the SGLT2 inhibitors inhibitors ▼ empagliflozin and ▼ canagliflozin.^2,3

This observational study compared cardiovascular mortality and morbidity in people with type 2 diabetes (mean age 61 years), of whom 25% had cardiovascular disease.¹ The …